Postprandial hyperglycemia and diabetes complications: Is it time to treat?

Diabetes

Volumn 54, Issue 1, 2005, Pages 1-7

  Ceriello, Antonio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; ACARBOSE; FREE RADICAL; GLIBENCLAMIDE; METFORMIN; NITRIC OXIDE; REPAGLINIDE; SUPEROXIDE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES CONTROL; DIABETES MELLITUS; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DNA DAMAGE; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; OXIDATIVE STRESS; POSTPRANDIAL PERIOD;

EID: 12144251636     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.1.1     Document Type: Review

References (97)

1. Kannel WB, McGee DL: Diabetes and cardiovascular diseases: the Framingham Study. JAMA 241:2035-2038, 1979
2. Laakso M: Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48:937-942, 1999
3. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44:2107-2114, 2001
4. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR, the UK Prospective Diabetes Study Group: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
5. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
6. UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
7. Vinik AI, Jenkins DJ: Dietary fiber in management of diabetes. Diabetes Care 11:160-1173, 1988
8. Wolever TMS, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA, Ryan EA: Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 21:336-340, 1998
9. de Vegt F, Dekker JM, Ruhè HG, Stehouwer CDA, Nijpels GBLM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42:926-931, 1999
10. Donahue RP, Abbott RD, Reed DM, Yano K: Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes 36:689-692, 1987
11. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men: the Chicago Heart Association Detection Project in Industry study. Diabetes Care 20:163-169, 1997
12. The DECODE Study Group, the European Diabetes Epidemiology Group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999
13. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
14. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A, Eschwège E: High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 21:360-367, 1998
15. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J, the DIS Group: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577-1583, 1996
16. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T: Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144:229-235, 1999
17. 1c level. Diabetes Care 23:1830-1834, 2000
18. Bellodi G, Manicardi V, Malavasi V, Veneri L,. Bernini G, Bossini P, Distefano S, Magnanini G, Muratori L, Rossi G: Hyperglycemia and prognosis of acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol 64:885-888, 1989
19. O' Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R: In hospital prognosis of patients with fasting hyperglycemia after first myocardial infarction. Diabetes Care 14:758-760, 1991
20. Gray CS, Taylor R, French JM, Alberti KG, Venables GS, James OF, Shaw DA, Cartlidge NE, Bates D: The prognostic value of stress hyperglycaemia and previosly unrecognized diabetes in acute stroke. Diabet Med 4:237-240, 1987
21. Gray CS, French JM, Bates D, Cartridge NE, Venables GS, James OF: Increasing age, diabetes mellitus and recovery from stroke. Postgrad Med J 65:720-742, 1989
22. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355:773-778, 2000
23. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation 99:2626-2632, 1999
24. Marfella R, Nappo F, De Angelis L, Siniscalchi M, Rossi F, Giugliano D: The effect of acute hyperglycaemia on QTc duration in healthy man. Diabetologia 43:571-575, 2000
25. Gokhroo R, Mitral SR: Electrocardiographic correlates of hyperglycemia in acute myocardial infarction. Int J Cardiol 22:267-269, 1989
26. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trail Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077, 2002
27. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
28. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T: Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 35:1073-1078, 2004
29. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
30. Esposito K, Giugliano D, Nappo F, Marfella R: Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 29:2978-2984, 2004
31. Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010-1014, 1994
32. Jenkins AJ, Klein RL, Chassereau CN, Hermayer KL, Lopes-Virella MF: LDL from patients with well-controlled IDDM is not more susceptible to in vitro oxidation. Diabetes 45:762-767, 1996
33. Diwadkar VA, Anderson JW, Bridges SR, Gowri MS, Oelgten PR: Postprandial low density lipoproteins in type 2 diabetes are oxidized more extensively than fasting diabetes and control samples. Proc Soc Exp Biol Med 222:178-184, 1999
34. Ceriello A, Bortolotti N, Motz E, Pieri C, Marra M, Tonutti L, Lizzio S, Feletto F, Catone B, Taboga C: Meal-induced oxidative stress and low-density lipoprotein oxidation in diabetes: the possible role of hyperglycemia. Metabolism 48:1503-1508, 1999
35. Jorgensen RG, Russo L, Mattioli L, Moore WV: Early detection of vascular dysfunction in type I diabetes. Diabetes 37:292-296, 1988
36. Marfella R, Verrazzo G, Acampora R, La Marca C, Giunta R, Lucarelli C, Paolisso G, Ceriello A, Giugliano D: Glutathione reverses systemic hemodynamic changes by acute hyperglycemia in healthy subjects. Am J Physiol 268:E1167-E1173, 1995
37. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H: Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34:146-154, 1999
38. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F: Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 95:1783-1790, 1997
39. Shige H, Ishikawa T, Suzukawa M, Ito T, Nakajima K, Higashi K, Ayaori M, Tabata S, Ohsuzu F, Nakamura H: Endothelium-dependent flow-mediated vasodilation in the postprandial state in type 2 diabetes mellitus. Am J Cardiol 84:1272-1274, 1999
40. Ceriello A: Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36:1119-1125, 1993
41. Jones RL, Peterson CM: Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest 63:485-493, 1979
42. Jones RL: Fibrinopeptide A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 34:836-841, 1985
43. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R: Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. Metabolism 38:1162-1163, 1989
44. Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E: Hyperglycemia-induced thrombin formation in diabetes: the possible role of the oxidative stress. Diabetes 44:924-928, 1995
45. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Torella R: Blood glucose may condition factor VII levels in diabetic and normal subjects. Diabetologia 31:889-891, 1988
46. Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, Soejima H, Kugiyama K, Yoshimura M, Yasue H: Rapid change of platelet aggregability in acute hyperglycemia: detection by a novel laser-light scattering method. Thromb Haemost 83:475-479, 2000
47. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel G, Motz E, Pirisi M: Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 39:469-473, 1996
48. Ruosladti E: Integrins. J Clin Invest 187:1-5, 1991
49. Lopes-Virella MF, Virella G: Immune mechanism of atherosclerosis in diabetes mellitus (Review). Diabetes 41 (Suppl. 2):86-91, 1992
50. Blann AD, McCollum CN: Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemostas 72:151-154, 1994
51. Cominacini L, Fratta Pasini A, Garbin U, Davoli A, De Santis A, Campagnola M, Rigoni A, Zenti MG, Moghetti P, Lo Cascio V: Elevated levels of soluble E-selectin in patients with IDDM and NIDDM: relation to metabolic control. Diabetologia 38:1122-1124, 1995
52. Ceriello A, Falleti E, Bortolotti N, Motz E, Cavarape A, Russo A, Gonano F, Bartoli E: Increased circulating ICAM-1 levels in type-2 diabetic patients: the possible role of metabolic control and oxidative stress. Metabolism 45:498-501, 1996
53. Ceriello A, Falleti E, Motz E, Taboga C, Tonutti L, Ezsol Z, Gonano F, Bartoli E: Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 30:146-149, 1998
54. Marfella R, Esposito K, Giunta R, Coppola G, De Angelis L, Farzati B, Prolisso G, Giugliano D: Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia. Circulation 101:2247-2251, 2000
55. Plutzky J: Inflammation in atherosclerosis and diabetes mellitus. Rev Endocr Metab Disord 5:255-259, 2004
56. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072, 2002
57. Nappo F, Esposito K, Cioffl M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D: Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39:1145-1150, 2002
58. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
59. Ceriello A: New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26:1589-1596, 2003
60. Title LM, Cummings PM, Giddens K, Nassar BA: Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: a effect prevented by vitamin C and E. J Am Coll Cardiol 36:2185-2191, 2000
61. Beckman JA, Goldfine AB, Gordon MB, Creager MA: Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans. Circulation 103:1618-1623, 2001
62. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Ézsol Z, Tonutti L, Taboga C: Antioxidant defenses are reduced during oral glucose tolerance test in normal and non-insulin dependent diabetic subjects. Eur J Clin Invest 28:329-333, 1998
63. Tessier D, Khalil A, Fulop T: Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J Gerrontol 54:541-545, 1999
64. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T: The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Invest 20:471-475, 1997
65. Ceriello A, Bortolotti N, Motz E, Crescentini A, Lizzio S, Russo A, Tonutti L, Taboga C: Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 21:1529-1533, 1998
66. Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E: The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 21:171-175, 2004
67. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E: Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25:1439-1443, 2002
68. Beckman JS, Koppenol WH: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271:C1424-C1437, 1996
69. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL, Gokce N, Keaney JF Jr, Penn MS, Sprecher DL, Vita JA, Hazen SL: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 289:1675-1680, 2003
70. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW: A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 107:853-860, 2001
71. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D: Acute hyperglycemia induces an oxidative stress in healthy subjects (Letter). J Clin Invest 108: 635-636, 2001
72. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E: Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106:1211-1218, 2002
73. Ceriello A, Quagliaro L, Piconi L, Assaloni R, Da Ros R, Maier A, Esposito K, Giugliano D: Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53:701-710, 2004
74. Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D: Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51:1076-1082, 2002
75. Mihm MJ, Jing L, Bauer JA: Nitrotyrosine causes selective vascular endothelial dysfunction and DNA damage. J Cardiovasc Pharmacol 36:182-187, 2000
76. Taskinen MR, Lahdenpera S, Syvanne M: New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med 28:335-340, 1996
77. Karpe F, de Faire U, Mercuri M, Bond MG, Hellenius ML, Hamsten A: Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis 141:307-314, 1998
78. Cavallero E, Dachet C, Neufcou D, Wirquin E, Mathe D, Jacotot B: Postprandial amplification of lipoprotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism 43:270-278, 1994
79. Heine RJ, Dekker JM: Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 45:461-475, 2002
80. Ceriello A, Motz E: Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816-823, 2004
81. De Caterina R: Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol 11:9-23, 2000
82. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995.
83. Avignon A, Radauceanu A, Monnier L: Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 20:1822-1826, 1997
84. Soonthornpun S, Rattarasarn C, Leelawattana R, Setasuban W: Postprandial plasma glucose: a good index of glycemic control in type 2 diabetic patients having near-normal fasting glucose levels. Diabetes Res Clin Pract 46:23-27, 1999
85. 1c. Diabetes Care 26:881-885, 2003
86. 1c in the Diabetes Control and Complications Trial. Diabetes Care 25:275-278, 2002
87. 1c: IOEZ Study Group. Diabetes Care 23:1236-1241, 2000
88. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients: U.K. Insulin Aspart Study Group. Diabetes Care 21:1904-1909, 1998
89. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl. 2):B21-B29, 2000
90. Singleton JR, Smith AG, Russell JW, Feldman EL: Microvascular complications of impaired glucose tolerance. Diabetes 52:2867-2873, 2003
91. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, World Health Org., 1999
92. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S15-S35, 2004
93. American College of Endocrinology: American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 8:5-11, 2002
94. Alberti KGMM, Gries FA: Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med 5:275-281, 1988
95. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 27 (Suppl. 2):1-163, 2003
96. De. Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk J, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D, the Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice: European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 24:1601-1610, 2003
97. American Diabetes Association: Postprandial blood glucose (Review). Diabetes Care 24:775-778, 2001